NIVESTYM™ Adverse Reactions

(filgrastim-aafi)

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

Splenic Rupture [see Warnings and Precautions (5.1)]
Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2)]
Serious Allergic Reactions [see Warnings and Precautions (5.3)]
Sickle Cell Disorders [see Warnings and Precautions (5.4)]
Glomerulonephritis [see Warnings and Precautions (5.5)]
Alveolar Hemorrhage and Hemoptysis [see Warnings and Precautions (5.6)]
Capillary Leak Syndrome [see Warnings and Precautions (5.7)]
Myelodysplastic Syndrome [see Warnings and Precautions (5.8)]
Acute Myeloid Leukemia [see Warnings and Precautions (5.8)]
Thrombocytopenia [see Warnings and Precautions (5.9)]
Leukocytosis [see Warnings and Precautions (5.10)]
Cutaneous Vasculitis [see Warnings and Precautions (5.11)]
Aortitis [see Warnings and Precautions (5.15)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions in Patients with Cancer Receiving Myelosuppressive Chemotherapy

The following adverse reaction data in Table 2 are from three randomized, placebo-controlled studies in patients with:

small cell lung cancer receiving standard dose chemotherapy with cyclophosphamide‚ doxorubicin‚ and etoposide (Study 1)
small cell lung cancer receiving ifosfamide, doxorubicin‚ and etoposide (Study 2), and
non-Hodgkin's lymphoma (NHL) receiving doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, and methotrexate ("ACVBP") or mitoxantrone, ifosfamide, mitoguazone, teniposide, methotrexate, folinic acid, methylprednisolone, and methotrexate ("VIM3") (Study 3).

A total of 451 patients were randomized to receive subcutaneous filgrastim 230 mcg/m2 (Study 1), 240 mcg/m2 (Study 2) or 4 or 5 mcg/kg/day (Study 3) (n = 294) or placebo (n = 157). The patients in these studies were median age 61 (range 29 to 78) years and 64% were male. The ethnicity was 95% Caucasian, 4% African American, and 1% Asian.

Table 2. Adverse Reactions in Patients with Cancer Receiving Myelosuppressive Chemotherapy (With ≥ 5% Higher Incidence in Filgrastim Compared to Placebo)
System Organ Class
Preferred Term
Filgrastim
(N = 294)
Placebo
(N = 157)
*
Percent difference (Filgrastim – Placebo) was 4%.

Blood and lymphatic system disorders

  Thrombocytopenia

38%

29%

Gastrointestinal disorders

  Nausea

43%

32%

General disorders and administration site conditions

  Pyrexia

48%

29%

  Chest pain

13%

6%

  Pain

12%

6%

  Fatigue

20%

10%

Musculoskeletal and connective tissue disorders

  Back pain

15%

8%

  Arthralgia

9%

2%

  Bone pain

11%

6%

  Pain in extremity*

7%

3%

Nervous system disorders

  Dizziness

14%

3%

Respiratory, thoracic and mediastinal disorders

  Cough

14%

8%

  Dyspnea

13%

8%

Skin and subcutaneous tissue disorders

  Rash

14%

5%

Investigations

  Blood lactate dehydrogenase increased

6%

1%

  Blood alkaline phosphatase increased

6%

1%

Adverse events with ≥ 5% higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy delivered included anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, edema peripheral, hemoglobin decreased, decreased appetite, oropharyngeal pain, and alopecia.

Adverse Reactions in Patients with Acute Myeloid Leukemia

Adverse reaction data below are from a randomized, double-blind, placebo-controlled study in patients with AML (Study 4) who received an induction chemotherapy regimen of intravenous daunorubicin days 1, 2, and 3; cytosine arabinoside days 1 to 7; and etoposide days 1 to 5 and up to 3 additional courses of therapy (induction 2, and consolidation 1, 2) of intravenous daunorubicin, cytosine arabinoside, and etoposide. The safety population included 518 patients randomized to receive either 5 mcg/kg/day filgrastim (n = 257) or placebo (n = 261). The median age was 54 (range 16 to 89) years and 54% were male.

Adverse reactions with ≥ 2% higher incidence in filgrastim patients compared to placebo included epistaxis, back pain, pain in extremity, erythema, and rash maculo-papular.

Adverse events with ≥ 2% higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy included diarrhea, constipation, and transfusion reaction.

Adverse Reactions in Patients with Cancer Undergoing Bone Marrow Transplantation

The following adverse reaction data are from one randomized, no treatment-controlled study in patients with acute lymphoblastic leukemia or lymphoblastic lymphoma receiving high-dose chemotherapy (cyclophosphamide or cytarabine, and melphalan) and total body irradiation (Study 5) and one randomized, no treatment-controlled study in patients with Hodgkin's disease (HD) and NHL undergoing high-dose chemotherapy and autologous bone marrow transplantation (Study 6). Patients receiving autologous bone marrow transplantation only were included in the analysis. A total of 100 patients received either 30 mcg/kg/day as a 4-hour infusion (Study 5) or 10 mcg/kg/day or 30 mcg/kg/day as a 24-hour infusion (Study 6) filgrastim (n = 72), no treatment control or placebo (n = 28). The median age was 30 (range 15 to 57) years, 57% were male.

Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included rash and hypersensitivity.

Adverse reactions in patients receiving intensive chemotherapy followed by autologous BMT with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included thrombocytopenia, anemia, hypertension, sepsis, bronchitis, and insomnia.

Adverse Reactions in Patients with Cancer Undergoing Autologous Peripheral Blood Progenitor Cell Collection

The adverse reaction data in Table 3 are from a series of 7 trials in patients with cancer undergoing mobilization of autologous peripheral blood progenitor cells for collection by leukapheresis. Patients (n = 166) in all these trials underwent a similar mobilization/collection regimen: filgrastim was administered for 6 to 8 days‚ in most cases the apheresis procedure occurred on days 5‚ 6, and 7. The dosage of filgrastim ranged between 5 to 30 mcg/kg/day and was administered subcutaneously by injection or continuous infusion. The median age was 39 (range 15 to 67) years, and 48% were male.

Table 3. Adverse Reactions in Patients with Cancer Undergoing Autologous PBPC in the Mobilization Phase (≥ 5% Incidence in Filgrastim Patients)
System Organ Class
Preferred Term
Mobilization Phase
(N = 166)

Musculoskeletal and connective tissue disorders

  Bone pain

30%

General disorders and administration site conditions

  Pyrexia

16%

Investigations

  Blood alkaline phosphatase increased

11%

Nervous system disorders

  Headache

10%

Adverse Reactions in Patients with Severe Chronic Neutropenia

The following adverse reaction data were identified in a randomized, controlled study in patients with SCN receiving filgrastim (Study 7). 123 patients were randomized to a 4-month observation period followed by subcutaneous filgrastim treatment or immediate subcutaneous filgrastim treatment. The median age was 12 years (range 7 months to 76 years) and 46% were male. The dosage of filgrastim was determined by the category of neutropenia. Initial dosage of filgrastim:

Idiopathic neutropenia: 3.6 mcg/kg/day
Cyclic neutropenia: 6 mcg/kg/day
Congenital neutropenia: 6 mcg/kg/day divided 2 times per day

The dosage was increased incrementally to 12 mcg/kg/day divided 2 times per day if there was no response.

Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included arthralgia, bone pain, back pain, muscle spasms, musculoskeletal pain, pain in extremity, splenomegaly, anemia, upper respiratory tract infection, and urinary tract infection (upper respiratory tract infection and urinary tract infection were higher in the filgrastim arm, total infection related events were lower in filgrastim-treated patients), epistaxis, chest pain, diarrhea, hypoesthesia, and alopecia.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of filgrastim products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

splenic rupture and splenomegaly (enlarged spleen) [see Warnings and Precautions (5.1)]
acute respiratory distress syndrome [see Warnings and Precautions (5.2)]
anaphylaxis [see Warnings and Precautions (5.3)]
sickle cell disorders [see Warnings and Precautions (5.4)]
glomerulonephritis [see Warnings and Precautions (5.5)]
alveolar hemorrhage and hemoptysis [see Warnings and Precautions (5.6)]
capillary leak syndrome [see Warnings and Precautions (5.7)]
leukocytosis [see Warnings and Precautions (5.10)]
cutaneous vasculitis [see Warnings and Precautions (5.11)]
Sweet's syndrome (acute febrile neutrophilic dermatosis)
decreased bone density and osteoporosis in pediatric patients receiving chronic treatment with filgrastim products.
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see Warnings and Precautions (5.8)]
aortitis [see Warnings and Precautions (5.15)]
extramedullary hematopoiesis

Find NIVESTYM™ medical information:

Find NIVESTYM™ medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

NIVESTYM™ Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

Splenic Rupture [see Warnings and Precautions (5.1)]
Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2)]
Serious Allergic Reactions [see Warnings and Precautions (5.3)]
Sickle Cell Disorders [see Warnings and Precautions (5.4)]
Glomerulonephritis [see Warnings and Precautions (5.5)]
Alveolar Hemorrhage and Hemoptysis [see Warnings and Precautions (5.6)]
Capillary Leak Syndrome [see Warnings and Precautions (5.7)]
Myelodysplastic Syndrome [see Warnings and Precautions (5.8)]
Acute Myeloid Leukemia [see Warnings and Precautions (5.8)]
Thrombocytopenia [see Warnings and Precautions (5.9)]
Leukocytosis [see Warnings and Precautions (5.10)]
Cutaneous Vasculitis [see Warnings and Precautions (5.11)]
Aortitis [see Warnings and Precautions (5.15)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions in Patients with Cancer Receiving Myelosuppressive Chemotherapy

The following adverse reaction data in Table 2 are from three randomized, placebo-controlled studies in patients with:

small cell lung cancer receiving standard dose chemotherapy with cyclophosphamide‚ doxorubicin‚ and etoposide (Study 1)
small cell lung cancer receiving ifosfamide, doxorubicin‚ and etoposide (Study 2), and
non-Hodgkin's lymphoma (NHL) receiving doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, and methotrexate ("ACVBP") or mitoxantrone, ifosfamide, mitoguazone, teniposide, methotrexate, folinic acid, methylprednisolone, and methotrexate ("VIM3") (Study 3).

A total of 451 patients were randomized to receive subcutaneous filgrastim 230 mcg/m2 (Study 1), 240 mcg/m2 (Study 2) or 4 or 5 mcg/kg/day (Study 3) (n = 294) or placebo (n = 157). The patients in these studies were median age 61 (range 29 to 78) years and 64% were male. The ethnicity was 95% Caucasian, 4% African American, and 1% Asian.

Table 2. Adverse Reactions in Patients with Cancer Receiving Myelosuppressive Chemotherapy (With ≥ 5% Higher Incidence in Filgrastim Compared to Placebo)
System Organ Class
Preferred Term
Filgrastim
(N = 294)
Placebo
(N = 157)
*
Percent difference (Filgrastim – Placebo) was 4%.

Blood and lymphatic system disorders

  Thrombocytopenia

38%

29%

Gastrointestinal disorders

  Nausea

43%

32%

General disorders and administration site conditions

  Pyrexia

48%

29%

  Chest pain

13%

6%

  Pain

12%

6%

  Fatigue

20%

10%

Musculoskeletal and connective tissue disorders

  Back pain

15%

8%

  Arthralgia

9%

2%

  Bone pain

11%

6%

  Pain in extremity*

7%

3%

Nervous system disorders

  Dizziness

14%

3%

Respiratory, thoracic and mediastinal disorders

  Cough

14%

8%

  Dyspnea

13%

8%

Skin and subcutaneous tissue disorders

  Rash

14%

5%

Investigations

  Blood lactate dehydrogenase increased

6%

1%

  Blood alkaline phosphatase increased

6%

1%

Adverse events with ≥ 5% higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy delivered included anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, edema peripheral, hemoglobin decreased, decreased appetite, oropharyngeal pain, and alopecia.

Adverse Reactions in Patients with Acute Myeloid Leukemia

Adverse reaction data below are from a randomized, double-blind, placebo-controlled study in patients with AML (Study 4) who received an induction chemotherapy regimen of intravenous daunorubicin days 1, 2, and 3; cytosine arabinoside days 1 to 7; and etoposide days 1 to 5 and up to 3 additional courses of therapy (induction 2, and consolidation 1, 2) of intravenous daunorubicin, cytosine arabinoside, and etoposide. The safety population included 518 patients randomized to receive either 5 mcg/kg/day filgrastim (n = 257) or placebo (n = 261). The median age was 54 (range 16 to 89) years and 54% were male.

Adverse reactions with ≥ 2% higher incidence in filgrastim patients compared to placebo included epistaxis, back pain, pain in extremity, erythema, and rash maculo-papular.

Adverse events with ≥ 2% higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy included diarrhea, constipation, and transfusion reaction.

Adverse Reactions in Patients with Cancer Undergoing Bone Marrow Transplantation

The following adverse reaction data are from one randomized, no treatment-controlled study in patients with acute lymphoblastic leukemia or lymphoblastic lymphoma receiving high-dose chemotherapy (cyclophosphamide or cytarabine, and melphalan) and total body irradiation (Study 5) and one randomized, no treatment-controlled study in patients with Hodgkin's disease (HD) and NHL undergoing high-dose chemotherapy and autologous bone marrow transplantation (Study 6). Patients receiving autologous bone marrow transplantation only were included in the analysis. A total of 100 patients received either 30 mcg/kg/day as a 4-hour infusion (Study 5) or 10 mcg/kg/day or 30 mcg/kg/day as a 24-hour infusion (Study 6) filgrastim (n = 72), no treatment control or placebo (n = 28). The median age was 30 (range 15 to 57) years, 57% were male.

Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included rash and hypersensitivity.

Adverse reactions in patients receiving intensive chemotherapy followed by autologous BMT with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included thrombocytopenia, anemia, hypertension, sepsis, bronchitis, and insomnia.

Adverse Reactions in Patients with Cancer Undergoing Autologous Peripheral Blood Progenitor Cell Collection

The adverse reaction data in Table 3 are from a series of 7 trials in patients with cancer undergoing mobilization of autologous peripheral blood progenitor cells for collection by leukapheresis. Patients (n = 166) in all these trials underwent a similar mobilization/collection regimen: filgrastim was administered for 6 to 8 days‚ in most cases the apheresis procedure occurred on days 5‚ 6, and 7. The dosage of filgrastim ranged between 5 to 30 mcg/kg/day and was administered subcutaneously by injection or continuous infusion. The median age was 39 (range 15 to 67) years, and 48% were male.

Table 3. Adverse Reactions in Patients with Cancer Undergoing Autologous PBPC in the Mobilization Phase (≥ 5% Incidence in Filgrastim Patients)
System Organ Class
Preferred Term
Mobilization Phase
(N = 166)

Musculoskeletal and connective tissue disorders

  Bone pain

30%

General disorders and administration site conditions

  Pyrexia

16%

Investigations

  Blood alkaline phosphatase increased

11%

Nervous system disorders

  Headache

10%

Adverse Reactions in Patients with Severe Chronic Neutropenia

The following adverse reaction data were identified in a randomized, controlled study in patients with SCN receiving filgrastim (Study 7). 123 patients were randomized to a 4-month observation period followed by subcutaneous filgrastim treatment or immediate subcutaneous filgrastim treatment. The median age was 12 years (range 7 months to 76 years) and 46% were male. The dosage of filgrastim was determined by the category of neutropenia. Initial dosage of filgrastim:

Idiopathic neutropenia: 3.6 mcg/kg/day
Cyclic neutropenia: 6 mcg/kg/day
Congenital neutropenia: 6 mcg/kg/day divided 2 times per day

The dosage was increased incrementally to 12 mcg/kg/day divided 2 times per day if there was no response.

Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included arthralgia, bone pain, back pain, muscle spasms, musculoskeletal pain, pain in extremity, splenomegaly, anemia, upper respiratory tract infection, and urinary tract infection (upper respiratory tract infection and urinary tract infection were higher in the filgrastim arm, total infection related events were lower in filgrastim-treated patients), epistaxis, chest pain, diarrhea, hypoesthesia, and alopecia.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of filgrastim products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

splenic rupture and splenomegaly (enlarged spleen) [see Warnings and Precautions (5.1)]
acute respiratory distress syndrome [see Warnings and Precautions (5.2)]
anaphylaxis [see Warnings and Precautions (5.3)]
sickle cell disorders [see Warnings and Precautions (5.4)]
glomerulonephritis [see Warnings and Precautions (5.5)]
alveolar hemorrhage and hemoptysis [see Warnings and Precautions (5.6)]
capillary leak syndrome [see Warnings and Precautions (5.7)]
leukocytosis [see Warnings and Precautions (5.10)]
cutaneous vasculitis [see Warnings and Precautions (5.11)]
Sweet's syndrome (acute febrile neutrophilic dermatosis)
decreased bone density and osteoporosis in pediatric patients receiving chronic treatment with filgrastim products.
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see Warnings and Precautions (5.8)]
aortitis [see Warnings and Precautions (5.15)]
extramedullary hematopoiesis
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.